Literature DB >> 31315954

Antimycobacterial Susceptibility Testing of Nontuberculous Mycobacteria.

Barbara A Brown-Elliott1, Gail L Woods2.   

Abstract

Recommendations for first-line and second-line drug testing and organism group, specific methodologies, and reporting recommendations have been addressed by the Clinical and Laboratory Standards Institute (CLSI) and are important in the selection of appropriate antimicrobial treatment regimens for nontuberculous mycobacteria (NTM) disease. This review also includes recent information on new antimicrobials proposed for the treatment of NTM but not yet addressed by the CLSI and molecular (gene sequencing) methods associated with the detection of antimicrobial resistance of two major therapeutic antimicrobials, clarithromycin and amikacin.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  mycobacteria; nontuberculous mycobacteria; susceptibility

Year:  2019        PMID： 31315954      PMCID： PMC6760954          DOI： 10.1128/JCM.00834-19

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  25 in total

Review 1.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

Review 2.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

3.  Intrinsic macrolide resistance in rapidly growing mycobacteria.

Authors:  Kevin A Nash; Nadya Andini; Yansheng Zhang; Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

4.  Activities of linezolid against rapidly growing mycobacteria.

Authors:  R J Wallace; B A Brown-Elliott; S C Ward; C J Crist; L B Mann; R W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 5.  Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections.

Authors:  Jerome A Lindeboom; Lesla E S Bruijnesteijn van Coppenraet; Dick van Soolingen; Jan M Prins; Eduard J Kuijper
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

6.  High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria.

Authors:  Gwan-Han Shen; Bo-Da Wu; Shiau-Ting Hu; Chen-Fu Lin; Kun-Ming Wu; Jiann-Hwa Chen
Journal:  Int J Antimicrob Agents       Date:  2010-04       Impact factor: 5.283

7.  A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.

Authors:  Kevin A Nash; Barbara A Brown-Elliott; Richard J Wallace
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

8.  Rapid molecular detection of inducible macrolide resistance in Mycobacterium chelonae and M. abscessus strains: a replacement for 14-day susceptibility testing?

Authors:  Kimberly E Hanson; E Susan Slechta; Haleina Muir; Adam P Barker
Journal:  J Clin Microbiol       Date:  2014-02-19       Impact factor: 5.948

9.  Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study.

Authors:  David E Griffith; Barbara A Brown-Elliott; Richard J Wallace
Journal:  Clin Infect Dis       Date:  2003-10-01       Impact factor: 9.079

10.  In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates.

Authors:  Barbara A Brown-Elliott; Elena Iakhiaeva; David E Griffith; Gail L Woods; Jason E Stout; Cameron R Wolfe; Christine Y Turenne; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2013-08-14       Impact factor: 5.948
View more
  15 in total

1.  Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue.

Authors:  Véronique Dartois; Thomas Dick
Journal:  J Exp Med       Date:  2022-05-11       Impact factor: 17.579

2.  Potential Cross-Transmission of Mycobacterium abscessus among Non-Cystic Fibrosis Patients at a Tertiary Hospital in Japan.

Authors:  Keiji Fujiwara; Mitsunori Yoshida; Yoshiro Murase; Akio Aono; Koji Furuuchi; Yoshiaki Tanaka; Ken Ohta; Manabu Ato; Satoshi Mitarai; Kozo Morimoto
Journal:  Microbiol Spectr       Date:  2022-05-10

3.  Clinical risk factors related to treatment failure in Mycobacterium abscessus lung disease.

Authors:  Keiji Fujiwara; Koji Furuuchi; Akio Aono; Fumiko Uesugi; Tatsuya Shirai; Keitaro Nakamoto; Takafumi Shimada; Fumi Mochizuki; Yoshiaki Tanaka; Hiroaki Iijima; Takashi Yoshiyama; Yuji Shiraishi; Atsuyuki Kurashima; Ken Ohta; Satoshi Mitarai; Kozo Morimoto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-09-01       Impact factor: 3.267

Review 4.  Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections.

Authors:  Jan-Willem Alffenaar; Anne-Grete Märtson; Scott K Heysell; Jin-Gun Cho; Asad Patanwala; Gina Burch; Hannah Y Kim; Marieke G G Sturkenboom; Anthony Byrne; Debbie Marriott; Indy Sandaradura; Simon Tiberi; Vitali Sintchencko; Shashikant Srivastava; Charles A Peloquin
Journal:  Clin Pharmacokinet       Date:  2021-03-10       Impact factor: 6.447

5.  Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report.

Authors:  Johanna Erber; Simon Weidlich; Tristan Tschaikowsky; Kathrin Rothe; Roland M Schmid; Jochen Schneider; Christoph D Spinner
Journal:  BMC Infect Dis       Date:  2020-05-24       Impact factor: 3.090

6.  Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi.

Authors:  Erdal Erol; Mariela Scortti; Jordan Fortner; Mukesh Patel; José A Vázquez-Boland
Journal:  J Clin Microbiol       Date:  2021-07-28       Impact factor: 5.948

Review 7.  General Overview of Nontuberculous Mycobacteria Opportunistic Pathogens: Mycobacterium avium and Mycobacterium abscessus.

Authors:  Kimberly To; Ruoqiong Cao; Aram Yegiazaryan; James Owens; Vishwanath Venketaraman
Journal:  J Clin Med       Date:  2020-08-06       Impact factor: 4.241

Review 8.  MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections.

Authors:  Jigar P Sethiya; Melanie A Sowards; Mary Jackson; Elton Jeffrey North
Journal:  Int J Mol Sci       Date:  2020-08-27       Impact factor: 5.923

9.  Mycobacterium agri Skin Infection in a Previously Healthy Patient: A Case Study.

Authors:  Chengan Xu; Wenhao Wu; Hongyi Pan; Tianchen Hui; Qingqing Wu; Zhewen Zhou; Shouhao Wang; Wei Zheng; Qiaoqiao Yi; Hongying Pan
Journal:  Infect Drug Resist       Date:  2021-07-28       Impact factor: 4.003

10.  Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease.

Authors:  Keiji Fujiwara; Fumiko Uesugi; Koji Furuuchi; Yoshiaki Tanaka; Takashi Yoshiyama; Mikio Saotome; Ken Ohta; Satoshi Mitarai; Kozo Morimoto
Journal:  Microbiol Spectr       Date:  2021-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.